Amgen To Highlight Cardiovascular Portfolio At American Heart Association Scientific Sessions 2015
Repatha™ (Evolocumab) Data Analysis Examines Effect of Dosing on LDL-C Reduction and Duration of ResponseCorlanor® (Ivabradine) Session Features Post-Hoc Safety Analysis of Continued Treatment in Patients Hospitalized With Worsening Heart Failure
Amgen - Investors - RSS Content
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.